This new edition of the World Federation of Hemophilia (WFH) guidelines for the
management of hemophilia comes at an exciting time in the evolution of the diagnosis and …

Background Despite the advantages of prophylactic treatment for hemophilia, patients tend
to discontinue or not adhere to it because of several challenges such as long-term use, high …

Bleeding with resultant hemophilic arthropathy constitutes the largest cause of morbidity in
patients with hemophilia. It results from repeated bleeding episodes in the joint and is …

The current standard of care for treating people with haemophilia (PWH) in the developed
world is prophylaxis with regular infusions of clotting factor concentrates. Gene therapy is …

Aims and objectives To describe the perceived burden on parents of children with severe or
moderate haemophilia and the impact of sociodemographic aspects and the child's medical …

Introduction: Haemophilia management and patients' quality of life significantly improved.
However, data on current patients', caregivers' and clinicians' satisfaction and limitations of …

Objective: This study examined the impact of adding two condition-specific bolt-on items to
the EQ-5D-5L and assessed their psychometric properties in patients with hemophilia …

Children with hemophilia are an enhanced risk of modifiable cardiovascular and metabolic
abnormalities. There is currently no nutritional guideline to prevent or manage …

Hemophilia is an X-linked recessive genetic disorder which affects approximately 400,000
people globally. Differing healthcare reimbursement systems, budgetary constraints and …

METHOD In December 2019, participants were identified from among the 21 PwH treated to
date with an investigational gene therapy product for haemophilia A or haemophilia B at the …